Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre Exploratory Phase II Study Describing the Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas

NCT04055220 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT04055220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04055220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre Exploratory Phase II Study Describing the Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
Lead sponsor
Centre Leon Berard
Phase
Not applicable
Overall status
Recruiting
Start date
March 3, 2020
Completion date
October 1, 2026
Enrollment
168 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

angiosarcoma, bone sarcoma, chondrosarcoma, ewing sarcoma, leiomyosarcoma, osteosarcoma, undifferentiated pleomorphic sarcoma